Navigation Links
Theravalues Confirms Beneficial Effects of Theracurmin™ on Diastolic Function in Hypertensive Patients
Date:11/10/2011

ORLANDO, Fla., Nov. 10, 2011 /PRNewswire/ -- Theravalues, a Japan based bio-venture, announced today that Theracurmin™, its curcumin-based product, impacts positively on the prevention of heart failure and its progression for the first time in history. During the human clinical trial started with the registration in July 2010, conducted by the company with National Hospital Organization Kyoto Medical Center and University of Shizuoka, Japan, the researchers found that Theracurmin™, which is absorbed by the body at a rate 27 times higher than curcumin powder, could effectively prevent diastolic failure.

(Logo:  http://photos.prnewswire.com/prnh/20111110/FL04434LOGO)

Dr. Tatsuya Morimoto, Professor at the Division of Molecular Medicine School of Pharmaceutical Sciences, at the University of Shizuoka said, "We are extremely excited to discover that Theracurmin™ has positive effects in curbing left ventricular diastolic failure at a statistically significant level." In the 24-week human trial, Theracurmin™, the absorption-enhanced curcumin invented by Theravalues, was prescribed for 30 subjects with left ventricular diastolic failure and their symptoms improved significantly. "The result of the study encourages patients and the elderly who have been suffering chronic cardiac problems," he added.

Curcumin, a polyphenol derived from turmeric (Curcuma Longa L,) has anti-inflammatory and anti-oxidant therapeutic properties. These properties effectively treat chronic inflammatory diseases. However, it has poor bioavailability due to its low oral absorption. Through Theracurmin™, Theravalues invented an innovative technology to solve this problem by creating surface controlled colloidal dispersion.

The FDA has approved Theracurmin™ for clinical trial in the United States. Last month, The University of Texas MD Anderson Cancer Center began treatment of malignant tumors caused by progressive cancer with Theracurmin™.

Mr. Hashimoto, the Representative Director and President of Theravalues said, "Theracurmin™ brings several exciting avenues of opportunity. We are confident about the potential power of Theracurmin™ not only for heart failure, but also for many incurable diseases and the maintenance of wellness of the people around the globe."

"While we were fascinated by the versatility of curcumin to help treat many diseases, its low oral absorption was the greatest challenge. Theracurmin™ improved the absorption of curcumin, making it 27 times higher than curcumin powder," said Dr. Koji Hasegawa, Director of the Division of Translational Research at National Hospital Organization Kyoto Medical Center. "In addition to its effectiveness on diastolic failure, we have been studying other application of Theracurmin™ to broaden its application into cancers, hepatic functions, skin conditions, ALS and Alzheimer's disease," he continued.

ABOUT THERAVALUES CORPORATION

Founded in 2007, Japan-based Theravalues Corporation strives to deliver better physical and mental health which gives much satisfaction to people around the world. Theravalues creates value through innovation, developing foods, medicines and technological models that achieve high satisfaction and healthy lives.

Learn more at www.theravalues.com/english  

Contact: Masami Hasegawa (Theravalues, Japan)
+81.3.3234.7677
mhasegawa@theravalues.com


'/>"/>
SOURCE Theravalues Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Chromos obtains interim order in connection with arrangement, announces annual and special meeting of shareholders and confirms mailing of information circular
2. Mylan Confirms First-to-File Patent Challenge Relating to Lescol(R)
3. Amylin Pharmaceuticals Confirms Receipt of Director Nomination Notices
4. Mylan Confirms Four First-to-File Challenges
5. GDFII/L&P Confirms Target Date Extension Of U.S. ITC Sucralose Ruling
6. NIH News Confirms Trend in Stem Cell Storage Facilities, says CEO of San Diego-based Bio-Matrix Scientific Group
7. Dow AgroSciences Confirms Efficacy of Zinc Finger Nucleases for Precise Genome Modification in Maize
8. Independent U.S. Study Confirms Veritides Ceeker(TM) Handheld Device Detects Anthrax With Outstanding Accuracy and Reliability
9. Independent Study Confirms Superior Properties of ZPC(TM) Enhanced Calcium Composite Bone Grafts
10. ImmuneRegen BioSciences Confirms Homsperas Therapeutic Anti-Influenza Effect on Pandemic H1N1 Influenza Virus After Oral Administration
11. Analysis confirms that nano-related research has strong multidisciplinary roots
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... -- CytRx Corporation (NASDAQ: CYTR ), a ... announced the appointment of Earl Warren Brien , ... healthcare investor, to its Board of Directors. ... strategic experience at the highest level," said Steven ... of the world,s leading orthopedic surgeons, Dr. Brien has ...
(Date:12/2/2016)... CA (PRWEB) , ... December 01, 2016 , ... ACEA ... from its Phase I/II clinical trials for AC0010 at the World Conference on Lung ... to providing an update on the phase I/II clinical trials for AC0010 in patients ...
(Date:12/2/2016)... ... 01, 2016 , ... Aerocom Healthcare ( http://www.aerocomhealthcare.com ), representing ... its chain-of-custody solution for tracking and securing medications at booth 676 at the ... , Aerocom has a proven solution for tracking medications via its system from ...
(Date:12/2/2016)... ... ... The Conference Forum has announced that the 3rd annual Immuno-Oncology 360° ... 1-3, 2017 at the Roosevelt Hotel in New York City. Led by advisors Dr ... approach, which addresses the most up-to-date information regarding business aspects, clinical advancements and scientific ...
Breaking Biology Technology:
(Date:11/22/2016)... -- According to the new market research report "Biometric System ... Voice), Multi-Factor), Component (Hardware and Software), Function (Contact and Non-contact), Application, and ... expected to grow from USD 10.74 Billion in 2015 to reach USD ... 2022. Continue Reading ... ...
(Date:11/19/2016)... DALLAS , Nov. 18, 2016 Securus ... technology solutions for public safety, investigation, corrections and monitoring, ... a smaller competitor, ICSolutions, to have an independent technology ... set, the most modern high tech/sophisticated telephone calling platform, ... tell customers that they do most of what we ...
(Date:11/16/2016)... Calif. , Nov. 16, 2016 ... user experience and security for consumer electronics, and ... the financial and retail industry, today announced a ... and convenient way to authenticate users of mobile ... Sensory,s TrulySecure™ software which requires no ...
Breaking Biology News(10 mins):